Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.

Cancer biology & therapy - 1 Jan 2015

Samulitis Betty K, Pond Kelvin W, Pond Erika, Cress Anne E, Patel Hitendra, Wisner Lee, Patel Charmi, Dorr Robert T, Landowski Terry H

Abstract excerpt

Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Chromatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Resistance, Neoplasm

Share to Gemcitabine

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25485960
DOI: 10.4161/15384047.2014.986967
PMCID: PMC4623403

Genes

CDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25485960-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.PMID 25485960Read ↗

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell linesSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

Challenges of drug resistance in the management of pancreatic cancerSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Semantic proximity Read ↗

Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.Semantic proximity Read ↗

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancerSemantic proximity Read ↗

Review. Molecular background of chemoresistance in pancreatic cancer.Semantic proximity Read ↗

Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotypeSemantic proximity Read ↗

Elevated PAF1-RAD52 axis confers chemoresistance to human cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.